title: Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.
abstract: Aberrant anaplastic lymphoma kinase (ALK) expression is a defining feature of many human cancers and was identified first in anaplastic large-cell lymphoma (ALCL), an aggressive non-Hodgkin T-cell lymphoma. Since that time, many studies have set out to identify the mechanisms used by aberrant ALK toward tumorigenesis. We have identified a distinct profile of micro-RNAs (miRNAs) that characterize ALCL; furthermore, this profile distinguishes ALK(+) from ALK(-) subtypes, and thus points toward potential mechanisms of tumorigenesis induced by aberrant ALK. Using a nucleophosmin-ALK transgenic mouse model as well as human primary ALCL tumor tissues and human ALCL-derived cell lines, we reveal a set of overlapping deregulated miRNAs that might be implicated in the development and progression of ALCL. Importantly, ALK(+) and ALK(-) ALCL could be distinguished by a distinct profile of "oncomirs": Five members of the miR-17-92 cluster were expressed more highly in ALK(+) ALCL, whereas miR-155 was expressed more than 10-fold higher in ALK(-) ALCL. Moreover, miR-101 was down-regulated in all ALCL model systems, but its forced expression attenuated cell proliferation only in ALK(+) and not in ALK(-) cell lines, perhaps suggesting different modes of ALK-dependent regulation of its target proteins. Furthermore, inhibition of mTOR, which is targeted by miR-101, led to reduced tumor growth in engrafted ALCL mouse models. In addition to future therapeutical and diagnostic applications, it will be of interest to study the physiological implications and prognostic value of the identified miRNA profiles.
authors.affiliation: Laboratory for Immunological and Molecular Cancer Research, Third Medical Department with Hematology, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria. o.merkel@salk.at
authors.forename: Olaf
authors.initials: O
authors.lastname: Merkel
authors.forename: Frank
authors.initials: F
authors.lastname: Hamacher
authors.forename: Daniela
authors.initials: D
authors.lastname: Laimer
authors.forename: Eveline
authors.initials: E
authors.lastname: Sifft
authors.forename: Zlatko
authors.initials: Z
authors.lastname: Trajanoski
authors.forename: Marcel
authors.initials: M
authors.lastname: Scheideler
authors.forename: Gerda
authors.initials: G
authors.lastname: Egger
authors.forename: Melanie R
authors.initials: MR
authors.lastname: Hassler
authors.forename: Christiane
authors.initials: C
authors.lastname: Thallinger
authors.forename: Ana
authors.initials: A
authors.lastname: Schmatz
authors.forename: Suzanne D
authors.initials: SD
authors.lastname: Turner
authors.forename: Richard
authors.initials: R
authors.lastname: Greil
authors.forename: Lukas
authors.initials: L
authors.lastname: Kenner
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001483:Base Sequence; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D020869:Gene Expression Profiling; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics* / Q000473:pathology; D051379:Mice; D008822:Mice, Transgenic; D035683:MicroRNAs / Q000235:genetics*; D005810:Multigene Family; D011505:Protein-Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*; D020794:Receptor Protein-Tyrosine Kinases; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D035683:MicroRNAs; C401859:temsirolimus; C000626173:ALK protein, human; C000626174:Alk protein, mouse; D000077548:Anaplastic Lymphoma Kinase; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases; D020123:Sirolimus
references.citation: Blood. 2010 May 27;115(21):4191-7
references.pmid: 20089965
references.citation: Oncogene. 2003 Jan 30;22(4):517-27
references.pmid: 12555065
references.citation: Br J Haematol. 2008 Mar;140(5):516-26
references.pmid: 18275429
references.citation: Blood. 1997 Oct 15;90(8):2901-10
references.pmid: 9376569
references.citation: J Virol. 2008 Sep;82(18):9065-74
references.pmid: 18596100
references.citation: Nat Med. 2005 Jun;11(6):623-9
references.pmid: 15895073
references.citation: Cancer Res. 2009 Feb 1;69(3):1135-42
references.pmid: 19155302
references.citation: Circ Res. 2009 May 22;104(10):1184-91
references.pmid: 19390056
references.citation: Oncogene. 2003 Oct 30;22(49):7750-61
references.pmid: 14586401
references.citation: Cell. 2004 Jan 23;116(2):281-97
references.pmid: 14744438
references.citation: Oncogene. 2007 Aug 16;26(38):5606-14
references.pmid: 17353907
references.citation: Am J Pathol. 2002 Jun;160(6):2309-10
references.pmid: 12057933
references.citation: Am J Pathol. 2002 Sep;161(3):875-83
references.pmid: 12213716
references.citation: FASEB J. 1997 Oct;11(12):965-72
references.pmid: 9337149
references.citation: Blood. 2007 Mar 1;109(5):2156-64
references.pmid: 17077326
references.citation: Br J Haematol. 1990 Feb;74(2):161-8
references.pmid: 2156548
references.citation: Blood. 1988 Jul;72(1):234-40
references.pmid: 3260522
references.citation: Mol Cancer Res. 2009 Sep;7(9):1466-76
references.pmid: 19737969
references.citation: Blood. 2007 Nov 1;110(9):3374-83
references.pmid: 17690253
references.citation: Nature. 2008 Oct 16;455(7215):971-4
references.pmid: 18923524
references.citation: Blood. 2003 Mar 1;101(5):1919-27
references.pmid: 12424201
references.citation: Nature. 2005 Jun 9;435(7043):828-33
references.pmid: 15944707
references.citation: Science. 2007 Apr 27;316(5824):608-11
references.pmid: 17463290
references.citation: Blood. 2007 Sep 1;110(5):1621-30
references.pmid: 17416736
references.citation: J Clin Oncol. 2009 Sep 10;27(26):4232-5
references.pmid: 19667260
references.citation: Cancer Res. 2009 Mar 15;69(6):2623-9
references.pmid: 19258506
references.citation: Nature. 2005 Jun 9;435(7043):839-43
references.pmid: 15944709
references.citation: J Immunol. 1980 Feb;124(2):879-84
references.pmid: 7188701
references.citation: Leukemia. 2009 Nov;23(11):2129-38
references.pmid: 19657361
references.citation: Cell. 2009 Jan 23;136(2):215-33
references.pmid: 19167326
references.citation: Cell Cycle. 2005 Sep;4(9):1131-3
references.pmid: 16082218
references.citation: Oncogene. 2002 Feb 7;21(7):1038-47
references.pmid: 11850821
references.citation: Blood. 1988 Sep;72(3):1045-7
references.pmid: 3416066
references.citation: Cancer Res. 2006 Jul 1;66(13):6589-97
references.pmid: 16818631
references.citation: Cell. 2009 Jun 12;137(6):1005-17
references.pmid: 19524505
references.citation: J Clin Oncol. 2010 Mar 20;28(9):1583-90
references.pmid: 20159827
references.citation: Science. 1994 Mar 4;263(5151):1281-4
references.pmid: 8122112
references.citation: Anticancer Res. 2006 Sep-Oct;26(5A):3275-9
references.pmid: 17094440
references.citation: Blood. 2009 Aug 20;114(8):1585-95
references.pmid: 19531656
references.citation: Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9
references.pmid: 16641092
references.citation: Science. 2008 Dec 12;322(5908):1695-9
references.pmid: 19008416
references.citation: Cell. 2008 Apr 18;133(2):217-22
references.pmid: 18423194